The Latest Breaking News from MCK

Mckesson Corporation (MCK) delivered better-than-expected earnings for the last quarter and updated its outlook for fiscal 2023. Wall Street analysts expect the stock to rise more than 18% in the near term. Therefore, it could be wise to buy this medical stock now. Read more….

With expanding medical needs and technological advancements, the healthcare industry’s prospects look impressive. Moreover, healthcare stocks tend to perform relatively well, irrespective of economic conditions, thanks to the inelastic demand for their products and services. Therefore, we think Nature’s Sunshine Products (NATR), Abbott Laboratories (ABT), Humana (HUM), Molina Healthcare (MOH),…

The medical industry is poised for growth this year, driven by expanding medical needs and increasing federal support. Moreover, the industry is expected to thrive in times of uncertainty due to steady demand. Thus, quality medical stocks McKesson Corp. (MCK) and Cardinal Health (CAH) could be ideal buys this year.…

Popular healthcare service provider McKesson (MCK) has delivered robust returns despite the market turbulence over the past year. Moreover, MCK’s solid fundamentals should help it to sustain its momentum. Thus, the stock might be an ideal buy for 2023. Keep reading.

Despite mass layoffs, the U.S. economy looks resilient enough to avoid a recession. Moreover, consumer sentiment remains pretty robust. Therefore, investors could consider buying quality stocks CVS Health (CVS), McKesson (MCK), and Archer-Daniels-Midland (ADM), which look poised to soar this year. Keep reading.

The Fed’s constant rate hikes have caused significant market volatility and increased recession fears. However, the Fed might slow the pace of hikes in the near term. While uncertainties remain, we think investors could consider buying fundamentally solid stocks McKesson (MCK), Molina Healthcare (MOH), Progress Software (PRGS), and Universal Logistics…

With the Fed’s continued interest-rate hikes expected to keep markets in perpetual turmoil, it would be opportune to load up on McKesson (MCK). The recession-resistant medical services market leader’s enduring competitive advantages and attractive valuation have also earned it a place in the portfolio of Warren Buffett-led Berkshire Hathaway (BRK).…

While the moderate inflation rate for November has boosted investor sentiment and may have paved the way for lower interest rate hikes from this month, Fed’s recent comments suggest that the target interest rate may be a bit further ahead. Hence shares of fundamentally strong businesses with robust demand, such…

With slowing inflation, indications of slower rate hikes by the Fed beginning this month, and resilient employment growth, fundamentally strong stocks AbbVie (ABBV), Oracle Corporation (ORCL), and McKesson (MCK) could be opportune investments now. Continue reading….

Markets have been highly volatile this year due to macroeconomic and geopolitical headwinds. However, signs of slowing inflation and dovish comments from the Fed Chair have renewed investor appetite for riskier assets. Hence, it could be wise to invest in the fastest-growing stocks, CVS Health (CVS), McKesson (MCK), Celestica (CLS),…

The Fed’s aggressive interest rate hikes this year have hurt growth stocks significantly. However, McKesson Corporation (MCK) has stood tall, becoming the second-best performing non-energy stock in the S&P 500 this year. With its growth expected to remain strong due to its strategic acquisition of Rx Savings Solutions (RxSS), it…